BioPharm America 2014 EBD Group MassBio

Share/Follow Us

Share this:
Follow this event:
Follow us on Twitter
Subscribe to our newsletters:

BioPharm America™ 2015 Program Overview

www.ebdgroup.com/bpa/program
Monday, September 14, 2015
6:00–8:00 pm
Level 3, Atrium
Welcome Reception

BioPharm America™ 2015 Welcome Reception
All BioPharm America attendees are cordially invited to join us for a welcome reception.

Boston Marriott Copley Place
110 Huntington Avenue
Boston, MA 02116 (map)

You will be able to pick up your name badge at the welcome reception.

Tuesday, September 15, 2015
7:30 am
7:30 am
Exhibition opens and Continental Breakfast
9:00–10:30 am
Parallel Workshops
The perfect pitch: Do you have what it takes to win over investors?

What you have to say in 30 seconds could mean the difference between a meeting with an investor and a door closed in your face. Win a one-to-one meeting with a leading life science private equity investor.

Members of the audience will have 30 seconds to give their elevator pitch to a star-studded panel of seasoned industry investors. The top picks will be selected for a second round that includes two minutes of presentation and/or Q&A time with the judges. First- and second-place winners will receive a full 30-minute private follow-up meeting with the panelist of their choice. Judges will receive a written summary of all participant pitches and their scores, should they wish to follow up on their own. All are welcome: entrepreneurs, service providers, job seekers, executives and more.

Audience preparation notes:
Participants will be judged on the quality and effectiveness of the overall 30-second pitch. Remember, the primary goal of an elevator pitch is to spark interest for a follow-up meeting. Pre-workshop coaching is available from the moderator (contact: doug@macbiocom.com). Practice, practice, practice!

Moderator:
Douglas MacDougall – President, MacDougall Biomedical Communications

Share this:Email this pageShare this on LinkedInShare this on Twitter
Big data: Going from buzzword to business

From genomics to drug discovery to compliance, the amount of data the biopharma industry has the ability collect and analyze is staggering. But, there are many questions to be addressed: How can we effectively mine the data to make impactful decisions in R&D? What information is being assessed by payers? Why are certain areas of biotech getting funded where others are not? This panel will address these questions and discuss how big data is being used to help companies more efficiently design clinical studies, enroll targeted patients, and ultimately help drive strategic business decisions.

Share this:Email this pageShare this on LinkedInShare this on Twitter
9:00–10:30 am
Pharma and Large Biotech Presentations

Moderator:
Ed Saltzman – President, Defined Health

9:10 am – Merck
9:30 am – AstraZeneca
9:50 am – Bayer HealthCare
10:10 am – Bristol-Myers Squibb
10:30 am – Johnson & Johnson Innovation
10:50 am – EMD Serono
11:10 am – Novo Nordisk
11:30 am – Sanofi
11:50 am – Vertex Pharmaceuticals

Share this:Email this pageShare this on LinkedInShare this on Twitter
10:45 am–12:30 pm
Welcome and Opening Plenary Discussion
Welcome Remarks

Speakers:
  • Anna Chrisman – Group Managing Director, EBD Group
  • Robert Coughlin – President and CEO, MassBio
Share this:Email this pageShare this on LinkedInShare this on Twitter
Opening Plenary Discussion
Giving up the corporate jet and going back to the trenches: Insights from biotech disrupters

There is an increasing number of industry heavy hitters who have successfully led and exited large corporations and are now investing their experience, clout and in some cases, personal finances to reseed the life science ecosystem by leading the charge at small companies. Join us as they provide their perspectives from both sides of the fence, share the "war stories" that got them to where they are, and discuss how their experiences are helping them drive innovative small companies to successfully attack difficult targets at the front lines.

Moderator:
Francois Maisonrouge – Senior Managing Director, Evercore Partners

Panelists:
  • Deborah Dunsire – President and CEO, FORUM Pharmaceuticals
  • Jeffrey B. Kindler – CEO, Centrexion Corp.
  • Jeremy Levin – Chairman and CEO, Ovid Therapeutics Inc.
  • Christopher A. Viehbacher – Managing Partner, Gurnet Point Capital
Share this:Email this pageShare this on LinkedInShare this on Twitter
Moderator:
Francois Maisonrouge Francois Maisonrouge
Senior Managing Director
Evercore Partners

Speakers:
Deborah Dunsire Jeffrey B. Kindler Jeremy Levin Christopher A. Viehbacher
Deborah Dunsire
President and CEO
FORUM Pharmaceuticals
Jeffrey B. Kindler
CEO
Centrexion Corp.
Jeremy Levin
Chairman and CEO
Ovid Therapeutics Inc.
Christopher A. Viehbacher
Managing Partner
Gurnet Point Capital
12:30–1:30 pm
Luncheon
1:30–6:15 pm
Parallel Panel Discussions
Dealmaking and Strategy
Rare diseases: The new norm?

With over 7,000 rare diseases and treatments for only 5% of them, the need for cures is obvious. With that need comes great opportunities—and risks—for drug developers. Though the therapeutic promises for the treatments of rare diseases are greater now than ever before, significant hurdles are in the way of getting patients access to innovative therapies. Heads of leading R&D companies and patient organizations will share their insights on the evolving landscape and discuss the importance of patient engagement and cross-sector collaborations in addressing the opportunities and challenges in financing, clinical trials, pricing, and patient access.

Share this:Email this pageShare this on LinkedInShare this on Twitter
Externalizing R&D, building efficient pharma

While attempting to maintain a continuous number of potential products, big pharma has had to adjust their acquisition and investment strategy due to declining R&D productivity in recent years. This has resulted in a significant shift from internal to external R&D, allowing industry to focus on scouting the most promising developments in biotech. The panel will discuss what is unique to their individual searches and how they prioritize.

Moderator:
Bruce Booth – Partner, Atlas Venture

Panelists:
  • Daniel J. Curran – Head, Center for External Innovation, Takeda Pharmaceuticals
  • Rupert Vessey – Senior VP, Translational Development, Celgene
Share this:Email this pageShare this on LinkedInShare this on Twitter
Instant biotech: Creating a clinical-stage startup by in-licensing assets

With numerous acquisitions and mergers among big pharma, and more programs from academics and biopharma than investors are willing to fund, many innovative, clinical-stage products that don't fit the mold are being left on the shelf. This leaves entrepreneurs in a perfect position to create startup companies with an instant pipeline. The panelists will discuss the multitude of options available when creating a biotech company by in-licensing assets, as well as their strategy on securing funding and the difficulties along the way.

Share this:Email this pageShare this on LinkedInShare this on Twitter
Off the Record Roundtables
How can we improve the outcome of non-dilutive funding?

There is a wide gap between what's being funded by the NIH and what actually gets to market. Why is this happening and what can industry do to improve it? Join this roundtable as we discuss the ways in which non-dilutive funding and industry can align to produce better outcomes.

Share this:Email this pageShare this on LinkedInShare this on Twitter
Digital health

Digital health is steadily growing and providing advances in the way health data is collected, organized and analyzed, which will influence patient treatment plans of the future. In years to come doctors may not only prescribe medicine, but also recommend a digital program for treatment. This panel will discuss how digital health has the potential to change the way therapeutics companies incorporate digital health into overall patient treatment strategies.

Share this:Email this pageShare this on LinkedInShare this on Twitter
How does pharma get involved in an outside-the-box idea?

Every pharma company boasts about being innovation-driven, yet the majority of their R&D targets and approaches are in the same five therapeutic areas. Sit down with executives from pharma going after the white space areas to discuss why going into these overlooked areas alone can actually be wildly successful.

Share this:Email this pageShare this on LinkedInShare this on Twitter
Biomarkers and precision medicine

Advancements in biomarkers and precision medicine have the potential to radically change disease treatment and prevention. With greater understanding of individual patient information, more targeted and tailored treatment options are available. Panelists will discuss how the future of biomarkers and personalized medicine will impact R&D decisions and ultimately benefit patients.

Share this:Email this pageShare this on LinkedInShare this on Twitter
1:00–6:00 pm
One-to-one Meetings ►
7:00–9:30 pm
Evening Networking Reception
Wednesday, September 16, 2015
7:30 am
7:30 am
Exhibition opens and Continental Breakfast
9:00–10:00 am
Pharma and Large Biotech Presentations

Moderator:
Ed Saltzman – President, Defined Health

9:10 am – Merck
9:30 am – AstraZeneca
9:50 am – Bayer HealthCare
10:10 am – Bristol-Myers Squibb
10:30 am – Johnson & Johnson Innovation
10:50 am – EMD Serono
11:10 am – Novo Nordisk
11:30 am – Sanofi
11:50 am – Vertex Pharmaceuticals

Share this:Email this pageShare this on LinkedInShare this on Twitter
8:00 am–6:00 pm
One-to-one Meetings ►
10:00 am–12:45 pm
Roundtable Discussions
Alternative partners roundtable

Clear methods are in place for how to approach pharma and even traditional investors but how do you get to the alternative partners that can make or break your startup? Venture philanthropists, patient groups, foundations and institutes discuss the best methods for getting the attention of all the other players.

Discussion leader:
  • Angus McQuilken – VP, Marketing and Communications, Massachusetts Life Sciences Center
Panelists:
  • Christopher de Souza – Director, Broadview Ventures
  • Gary M. Sclar – Associate Director, Dana-Farber Cancer Institute
Share this:Email this pageShare this on LinkedInShare this on Twitter
Pharma roundtable

Hear directly from your potential deal partners (large and small): What are they are looking for? Where do they source from? How do you get their attention? Execs from the leading pharma companies will share "dos and don'ts" and other helpful advice going into your afternoon pitches.

Share this:Email this pageShare this on LinkedInShare this on Twitter
Investor roundtable

Investors with backgrounds in traditional venture capital, angel investing, and venture philanthropy will highlight innovative financing methods for early stage companies. Building relationships and perfecting your pitch are keys to securing funding, so panelists will also discuss when and how to approach investors with your business proposition.

Discussion leader:
  • Steve Dickman – CEO, CBT Advisors
Share this:Email this pageShare this on LinkedInShare this on Twitter
12:30–1:30 pm
Luncheon
1:30–4:30 pm
Afternoon pitches by startup companies

Pitch your startup to a panel of judges comprising BD execs, venture capitalists, and industry experts!

Qualifying startup companies are invited to pitch their company using no more than four slides (or no slides if you dare!) in four minutes. Our top-notch panel of judges will determine the winner by the quality and effectiveness of the pitch.

Moderator:
Douglas MacDougall – President, MacDougall Biomedical Communications

Share this:Email this pageShare this on LinkedInShare this on Twitter
1:30–4:30 pm
Company Presentations ►
Thursday, September 17, 2015
7:30 am
7:30 am
Exhibition opens and Continental Breakfast
8:30 am–12:30 pm
Company Presentations ►
8:00 am–3:00 pm
One-to-one Meetings ►
9:15–10:15 am
Opening Panel Discussion
The evolution of the Regen Med ecosystem: What's required for its growth and sustainability?

The Boston area is rich with innovative Regen Med companies and flush with cash from investors but is that enough? It takes more than hot technologies to build a viable business and more importantly, make an impact in patients' lives. What does the Regen Med/Cell and Gene Therapy sector need to become sustainable long-term? Panelists will discuss the need for an integrated approach to building the necessary infrastructure for success and help define the critical roles of startups, established biopharma, clinicians, manufacturers, and other stakeholders that can make or break this maturing industry.

Share this:Email this pageShare this on LinkedInShare this on Twitter
10:30 am–12:45 pm
Panel Discussions
Gene and cell therapy

With breaking headlines on how gene therapy can transform the way we treat diseases, the sector is booming. This panel will discuss the latest industry advances, new partnerships, regulatory issues, and other exciting developments.

Share this:Email this pageShare this on LinkedInShare this on Twitter
Genome editing

We have seen exciting progress in the field of gene editing but how are these advances being applied to cell therapy and disease modification? How are techniques used in the lab like CRISPR and TALENS being translated to real benefits in patients, especially those with heredity diseases? In addition to the scientific advances, what regulatory issues will need to be addressed before we can see treatments? What can we expect to see in the near and long-term?

Share this:Email this pageShare this on LinkedInShare this on Twitter
12:30–1:30 pm
Luncheon
3:00–4:00 pm
Closing Reception
Arrow Up


© 2009–2015 EBD Group, Inc.